|Articles|June 9, 2022
- Pharmaceutical Executive-06-01-2022
- Volume 42
- Issue 6
Pharmaceutical Executive, June 2022 Issue (PDF)
Advertisement
Articles in this issue
about 4 years ago
2022 Pharm Exec Top 50 Companiesabout 4 years ago
The Emergence of the Chief Value Officer in Healthcareabout 4 years ago
Sustainability Sea Change: The Top 5 ESG Challenges for Pharmaabout 4 years ago
Is the C-Suite Getting Inflated?about 4 years ago
Clinical Composerabout 4 years ago
Are We Closer Than Ever to a Biotech Bottom?about 4 years ago
DE&I in Pharma: Good for People—and Businessabout 4 years ago
Early Input Necessary in Creating Smooth C-Suite Transitionsabout 4 years ago
A Storm in a Brussels Teacup Could Threaten Drug-Pricing Watersabout 4 years ago
Fresh Talent Awaits, But Must Be Tech-SavvyAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes
3
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
4
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
5